Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience

被引：4
|
作者：
Suleman, Adam [1 ]
Liu, Jiajia [1 ]
Hicks, Lisa K. [1 ,2 ]
Drori, Adi Klil [3 ]
Crump, Michael [1 ,4 ]
Kridel, Robert [1 ,4 ]
Prica, Anca [1 ,4 ]
Berinstein, Neil [1 ,5 ]
机构：
[1] Univ Toronto, Fac Med, Toronto, ON, Canada
[2] St Michaels Hosp, Div Med Oncol & Hematol, Toronto, ON, Canada
[3] AbbVie Inc, N Chicago, IL USA
[4] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[5] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada
来源：
HAEMATOLOGICA | 2023年 / 108卷 / 04期
关键词：
D O I：
10.3324/haematol.2022.282014
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1186 / 1189
页数：4
相关论文
共 50 条
  • [21] The addition of thiotepa and rituximab to methotrexate and cytarabine (MATRix regimen) in primary lymphomas of the central nervous system improves the overall response rate and overall survival: results of a Phase II study of the International Extranodal Lymphoma Study Group-32
    Systchenko, Thomas
    Cayssials, Emilie
    Leleu, Xavier
    Guidez, Stephanie
    HEMATOLOGIE, 2016, 22 (04): : 253 - +
  • [22] Methotrexate in Combination with Orelabrutinib, Thiotepa, and Rituximab (R-MTO) Followed By Autologous Stem-Cell Transplant for Primary Central Nervous System Lymphoma Treatment
    Xing, Lijie
    Wei, Haichen
    Liu, Dan
    Wang, Hui
    Li, Ping
    Xie, Linna
    Li, Zengjun
    BLOOD, 2023, 142
  • [23] Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphoma
    Lebel, Eyal
    Goldschmidt, Neta
    Siegal, Tali
    Lossos, Alexander
    Rosenberg, Shai
    Makranz, Chen
    Linetski, Eduard
    Gatt, Moshe E.
    Gural, Alexander
    Saban, Revital
    Lavie, David
    Vainstein, Vladimir
    Zimran, Eran
    Avni, Batia
    Grisaro, Sigal
    Shaulov, Adir
    Nachmias, Boaz
    LEUKEMIA & LYMPHOMA, 2022, 63 (09) : 2102 - 2108
  • [24] The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma
    Van Dijck, Ruben
    Doorduijn, Jeanette K.
    Bromberg, Jacoline E. C.
    CANCERS, 2021, 13 (08)
  • [25] Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly
    Antonio M. P. Omuro
    Luc Taillandier
    Olivier Chinot
    Charlotte Carnin
    Maryline Barrie
    Khe Hoang-Xuan
    Journal of Neuro-Oncology, 2007, 85 : 207 - 211
  • [26] Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly
    Omuro, Antonio M. P.
    Taillandier, Luc
    Chinot, Olivier
    Carnin, Charlotte
    Barrie, Maryline
    Hoang-Xuan, Khe
    JOURNAL OF NEURO-ONCOLOGY, 2007, 85 (02) : 207 - 211
  • [27] Role of intrathecal methotrexate in primary central nervous system lymphoma
    Khan, RB
    DeAngelis, LM
    Abrey, LE
    NEUROLOGY, 2001, 56 (08) : A409 - A410
  • [28] High-dose methotrexate and temozolomide associated with intrathecal liposomal cytarabine for the treatment of primary or secondary central nervous system lymphoma: A preliminary experience
    Falchi, Lorenzo
    Gunnellini, Marco
    Ferranti, Lucia
    Liberati, Anna Marina
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2012, 114 (10) : 1376 - 1378
  • [29] Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapy
    Yuen, Hiu Lam Agnes
    Slocombe, Alison
    Heron, Vanessa
    Chunilal, Sanjeev
    Shortt, Jake
    Tatarczuch, Maciej
    Grigoriadis, George
    Patil, Sushrut
    Gregory, Gareth P.
    Opat, Stephen
    Gilbertson, Michael
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2020, 4 (06) : 997 - 1003
  • [30] HIGH-DOSE METHOTREXATE, HIGH-DOSE CYTARABINE AND TEMOZOLOMIDE FOR THE TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
    Salamoon, M.
    Hussein, T.
    Kenj, M.
    HAEMATOLOGICA, 2013, 98 : 355 - 355
12345